Covid-19 Research

Open Access
Short Communication
OCLC 8667244991

Treatment of People with Evans Syndrome in the Setting of COVID-19 Pandemic Google Scholar

Read • Cite • Share — permanent Open Access hosting with DOI tracking
Medicine Group
HematologyNeurooncologyBlood Disorders
Article Submission Portal

Volume1-Issue5
Dates: Received: 2020-08-21 | Accepted: 2020-09-16 | Published: 2020-09-18
Pages: 160-162

Abstract

A new type of pneumonia had developed from Wuhan Province in China in December 2019, caused by a novel member of the Coronaviridae family named Severe Acute Respiratory Coronavirus 2 Syndrome (SARS-CoV-2) [1]. The disease is characterized by fatigue, dry cough, fever, and dyspnea [2]. In a more severe case, the picture may become more complicated by the onset of interstitial pneumonia with alveolar damage, which clinically can lead to severe Acute Respiratory Distress Syndrome (ARDS) and even death [3]. Since the initial outbreak, the epidemic has had a rapid global spread worldwide, which led the World Health Organization (WHO) to declare the disease now called COVID-19, a pandemic on 11th March 2020 [4].

FullText HTML FullText PDF DOI: 10.37871/jbres1137

Certificate of Publication

Copyright

© 2020 Abbas AM, et al. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Abbas AM, Helbawi FM, Abdelsalam MH. Treatment of People with Evans Syndrome in the Setting of COVID-19 Pandemic. J Biomed Res Environ Sci. 2020 Sep 18; 1(5): 160-162. doi: 10.37871/jbres1137, Article ID: jbres1137

Subject area(s)

Hematology
Neurooncology
Blood Disorders

University/Institute

Assiut University

References

  1. Zhou P, Yang
  2. XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated
  3. with a new coronavirus of probable bat origin. Nature. 2020; 579: 270-273.
  4. DOI:
  5. 1038/s41586-020-2012-7
  6. Wu Z, McGoogan
  7. JM. Characteristics of and important lessons from the Coronavirus Disease 2019
  8. (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the
  9. Chinese center for disease control and prevention. JAMA. 2020.
  10. DOI:
  11. 1001/jama.2020.2648
  12. Yang X, Yu Y,
  13. Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically
  14. ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single centered,
  15. retrospective, observational study. Lancet Respir Med. 2020; 8: 475-481.
  16. DOI:
  17. 1016/S2213-2600(20)30079-5
  18. https://experience.arcgis.com/experience/685d0ace521648f8a5beee1b9125cd
  19. (Accessed 20th August 2020).
  20. Favalli EG,
  21. Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection
  22. and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020; 19: 102523.
  23. DOI:
  24. 1016/j.autrev.2020.102523
  25. Barcellini W,
  26. Giannotta J, Fattizzo B. Autoimmune hemolytic anemia in adults: Primary risk
  27. factors and diagnostic procedures. Exp Rev Hematol. 2020; 13: 585-597.
  28. DOI:
  29. 1080/17474086.2020.1754791
  30. Mendonca S,
  31. Srivastava S, Kapoor R, Gupta D, Gupta P, Sharma ML. Evans syndrome and its
  32. link with systemic lupus erythematosus. Saudi J Kidney Dis Transpl. 2016; 27:
  33. 147-149.
  34. DOI:
  35. 4103/1319-2442.174177
  36. Rodeghiero F,
  37. Marranconi E. Management of immune thrombocytopenia in women: Current standards
  38. and special considerations. Exp Rev Hematol. 2020; 13: 175-185.
  39. DOI:
  40. 1080/17474086.2020.1711729
  41. Tang NL, Chan
  42. PK, Wong CK, To KF, Wu AK, Sung YM, et al. Early enhanced expression of
  43. interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse
  44. outcome in severe acute respiratory syndrome. Clin Chem. 2005; 51: 2333-2340.
  45. DOI:
  46. 1373/clinchem.2005.054460
  47. Arabi YM,
  48. Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al.
  49. Corticosteroid therapy for critically ill patients with Middle East respiratory
  50. syndrome. Am J Respir Crit Care Med. 2018; 197: 757-767.
  51. DOI:
  52. 1164/rccm.201706-1172OC
  53. Stockman LJ,
  54. Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS
  55. medicine. 2006; 3: e343.
  56. DOI:
  57. https://dx.doi.org/10.1371/journal.pmed.0030343
  58. Zumla A, Hui
  59. DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015; 386: 995-1007.
  60. DOI:
  61. 1016/S0140-6736(15)60454-8
  62. Rosa SG,
  63. Santos WC. Clinical trials on drug repositioning for COVID-19 treatment.
  64. Revista Panamericana de Salud Pública. 2020; 44: e40.
  65. DOI:
  66. 26633/RPSP.2020.40
  67. Russell CD,
  68. Millar JE, Baillie JK. Clinical evidence does not support corticosteroid
  69. treatment for 2019-nCoV lung injury. Lancet. 2020; 395: 473-475.
  70. DOI:
  71. 1016/S0140-6736(20)30317-2
  72. Gao J, Tian Z,
  73. Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in
  74. treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends
  75. 2020; 14: 72-73.
  76. DOI:
  77. 5582/bst.2020.01047
  78. Chen J, Liu D,
  79. Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in
  80. treatment of patients with moderate COVID-19. J Zhejiang Univ. 2020; 49:
  81. 215-219.
  82. DOI:
  83. 3785/j.issn.1008-9292.2020.03.03
  84. Parperis K. To
  85. consider or not antimalarials as a prophylactic intervention in the SARS-CoV-
  86. 2(COVID-19) pandemic. Ann Rheum Dis. 2020; annrheumdis-2020-217557.
  87. DOI:
  88. 1136/annrheumdis-2020-217557
  89. Papachristodoulou
  90. E, Kakoullis L, Parperis K, Panos G. Long-term and herd immunity against
  91. SARS-CoV-2: Implications from current and past knowledge. Pathog Dis. 2020; 78.
  92. DOI:
  93. 1093/femspd/ftaa025
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership